Biocon announced its Q3 FY26 financial results on February 13, 2026, showcasing significant year-over-year (YoY) improvements across several metrics. Total Revenue grew 11% YoY to ₹4,290 Cr. Core EBITDA saw a 21% YoY jump, hitting ₹1,221 Cr with a margin of 29%. Net Profit (Reported) surged by an impressive 475% YoY to ₹144 Cr, signaling a transition toward sustainable growth and margin expansion.
Q3 FY26 Financial Performance Summary
Biocon reported strong consolidated results for the third quarter of the financial year 2026. Revenue from Operations stood at ₹4,173 Cr, marking a 9% YoY increase, while Total Revenue grew 11% YoY to ₹4,290 Cr. The company achieved a strong Core EBITDA of ₹1,221 Cr, a 21% YoY improvement, resulting in a margin of 29% (up from 26% in Q3 FY25). Profit Before Tax (before exceptional items) was ₹226 Cr, up 64% YoY.
Reported Net Profit showed substantial growth, surging 475% YoY to ₹144 Cr (compared to ₹25 Cr in Q3 FY25), reflecting significant positive momentum.
Segmental Revenue Deep Dive
The Biosimilars segment remains the largest contributor to revenue, achieving ₹2,497 Cr, up 9% YoY. The Generics segment demonstrated robust growth, with revenue increasing 24% YoY to ₹851 Cr. The CRDMO segment recorded revenue of ₹917 Cr, showing a 3% YoY decline, attributed to challenges with a single manufacturing customer which are expected to normalize.
Business Highlights and Strategic Updates
Biosimilars Performance Update
Biocon Biologics reported segment revenue of ₹2,497 Cr, driven primarily by North America where revenue grew 9% YoY. Core EBITDA for this segment rose 37% YoY to ₹895 Cr, yielding a strong margin of 35% of segment revenue. Key developments included strong commercial traction for Yesintek and the expansion of the Civica partnership for affordable Insulin Glargine.
Generics Segment Momentum
The Generics business revenue grew 24% YoY to ₹851 Cr, largely fueled by ongoing gLiraglutide launches across EU markets. EBITDA for the segment was ₹47 Cr, up 22% YoY. The segment also saw key regulatory progress, including US FDA EIRs (VAI) for key manufacturing units.
CRDMO Business Resilience
The CRDMO segment revenue was ₹917 Cr in Q3 FY26. Reported EBITDA for the segment was ₹225 Cr, though it declined 26% YoY due to transient customer challenges. The company highlighted client momentum, including the extension of the BMS partnership through to 2035, and continued platform expansion with new facility commissioning.
Concluding Remarks
The management expressed confidence in the ability to deliver long-term value for stakeholders, emphasizing strong progress across the product portfolio, go-to-market execution, and a focus on sustainable growth, margin expansion, and improving RoCE.
Source: BSE
